HENDERSON, Nev., March 20, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung ...

HENDERSON, Nev., March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that ...

HENDERSON, Nev., March 11, 2025 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces first patient enrollment in a clinical study ...

HENDERSON, Nev., March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer ...

Gael Forterre, Chief Commercial Officer at Volition commented: "We are in active discussions regarding our cancer portfolio with several large diagnostics and liquid biopsy companies, with the ...